Biosimilar sourcing is no longer a procurement exercise—it’s an IP strategy.
If you’re planning a switch from an originator biologic to a biosimilar, the hardest part isn’t finding a supplier. It’s timing the switch so you don’t get blindsided by exc…

Pharma has a familiar playbook: take an old molecule, repackage the story, and charge like it’s new.
That’s the tension at the heart of “old drugs, new prices”—a strategy increasingly used for repurposed medicines, where companies argue that premium pr…

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russia’s drug strategy is often described in headlines as a “self-reliance” push. But the real story is hiding in plain sight: patent filings.
In a world where supply chains are fragile and regulatory timelines are opaque, the most reliable early-warni…

Europe’s patent system is supposed to be a referee—clear rules, final calls, and predictable outcomes. But lately, it’s been looking more like a maze: big pharma can keep generics waiting by steering disputes into procedural limbo, where “eventual” dec…

Pharma patent litigation used to be a $50M inevitability.
Now, it’s increasingly a $5M decision—if you design the strategy before the first complaint is filed.
That’s the core message behind a new playbook from DrugPatentWatch: cutting the cost of pate…

PBMs and rebates are no longer “back-office” topics. They’re board-level risk.
If you’re a pharma executive—commercial, strategy, finance, or legal—your next earnings cycle may hinge less on your pipeline slide and more on what happens after launch: fo…

Mark Cuban’s “cost-plus” pricing isn’t just a pricing tweak—it’s a direct challenge to the patent playbook that’s defined Big Pharma for decades.
For years, the industry’s story has been consistent: innovation is expensive, patents are necessary to rec…